open access

Ahead of Print
Research paper
Published online: 2021-04-12
Get Citation

Role of serum organic solute transporter alpha/beta and sodium taurocholate cotransporting polypeptide in intrahepatic cholestasis of pregnancy

Kader İrak, Mehmet Bayram, Sami Cifci, Zuat Acar, Cemal Kazezoğlu, Elif Yorulmaz, Suleyman Yildirim
DOI: 10.5603/GP.a2021.0063
·
Pubmed: 33844255

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2021-04-12

Abstract

Objectives: This study aimed to assess the role of OST-α, OST-β and NTCP in patients with ICP, with a view to determine patients with severe prognosis and to minimize adverse fetal outcomes.

Material and methods: Sixty-nine pregnant women diagnosed with ICP and 50 healthy women were included the study. Serum OST-α, OST-β and NTCP were measured using ELISA kits.

Results: The median OST-α levels were 176.3 pg/mL in women with ICP and 201 pg/mL in healthy subjects (p = 0.205). The median OST-β levels were found to be 51.17 pg/mL in patients with ICP and 40.9 pg/mL in controls (p = 0.033). Median NTCP levels were 519.7 ng/mL in the ICP group and 483.3 ng/mL in healthy women (p = 0.051).

Conclusions: This is the first study to evaluate serum levels of OST-α, OST-β and NTCP in patients with ICP. It is likely that OST-α, OST-β and NTCP contribute to the etiopathogenesis of ICP. Serum OST-α and OST-β levels can be used as diagnostic and monitoring markers of ICP, and the inhibition of these molecules could provide therapeutic benefit in ICP by reducing the circulation of enterohepatic bile acids.

Abstract

Objectives: This study aimed to assess the role of OST-α, OST-β and NTCP in patients with ICP, with a view to determine patients with severe prognosis and to minimize adverse fetal outcomes.

Material and methods: Sixty-nine pregnant women diagnosed with ICP and 50 healthy women were included the study. Serum OST-α, OST-β and NTCP were measured using ELISA kits.

Results: The median OST-α levels were 176.3 pg/mL in women with ICP and 201 pg/mL in healthy subjects (p = 0.205). The median OST-β levels were found to be 51.17 pg/mL in patients with ICP and 40.9 pg/mL in controls (p = 0.033). Median NTCP levels were 519.7 ng/mL in the ICP group and 483.3 ng/mL in healthy women (p = 0.051).

Conclusions: This is the first study to evaluate serum levels of OST-α, OST-β and NTCP in patients with ICP. It is likely that OST-α, OST-β and NTCP contribute to the etiopathogenesis of ICP. Serum OST-α and OST-β levels can be used as diagnostic and monitoring markers of ICP, and the inhibition of these molecules could provide therapeutic benefit in ICP by reducing the circulation of enterohepatic bile acids.

Get Citation

Keywords

bile acids; intrahepatic cholestasis of pregnancy; organic solute transporter alpha/beta; sodium taurocholate cotransporting polypeptide

About this article
Title

Role of serum organic solute transporter alpha/beta and sodium taurocholate cotransporting polypeptide in intrahepatic cholestasis of pregnancy

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2021-04-12

DOI

10.5603/GP.a2021.0063

Pubmed

33844255

Keywords

bile acids
intrahepatic cholestasis of pregnancy
organic solute transporter alpha/beta
sodium taurocholate cotransporting polypeptide

Authors

Kader İrak
Mehmet Bayram
Sami Cifci
Zuat Acar
Cemal Kazezoğlu
Elif Yorulmaz
Suleyman Yildirim

References (26)
  1. Kumar S, Puri P, Gujral K. Intrahepatic cholestasis of pregnancy. Current Medicine Research and Practice. 2018; 8(6): 230–234.
  2. Çelik S, Çalışkan CS, Çelik H, et al. Predictors of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy. Ginekol Pol. 2019; 90(4): 217–222.
  3. Smith DD, Rood KM. Intrahepatic Cholestasis of Pregnancy. Clin Obstet Gynecol. 2020; 63(1): 134–151.
  4. Piechota J, Jelski W. Intrahepatic Cholestasis in Pregnancy: Review of the Literature. J Clin Med. 2020; 9(5).
  5. Beaudoin JJ, Brouwer KLR, Malinen MM. Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside. Pharmacol Ther. 2020; 211: 107542.
  6. Ferrebee CB, Li J, Haywood J, et al. Organic Solute Transporter α-β Protects Ileal Enterocytes From Bile Acid-Induced Injury. Cell Mol Gastroenterol Hepatol. 2018; 5(4): 499–522.
  7. Chen R, Deng M, Rauf YM, et al. Intrahepatic Cholestasis of Pregnancy as a Clinical Manifestation of Sodium-Taurocholate Cotransporting Polypeptide Deficiency. Tohoku J Exp Med. 2019; 248(1): 57–61.
  8. Karpen SJ, Dawson PA. Not all (bile acids) who wander are lost: the first report of a patient with an isolated NTCP defect. Hepatology. 2015; 61(1): 24–27.
  9. Tayyar AT, Tayyar A, Kozali S, et al. Evaluation of FGF-19 and β-klotho as biomarkers in patients with intrahepatic cholestasis of pregnancy. Arch Med Sci. 2019; 15(1): 113–119.
  10. Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile Acid Physiology. Ann Hepatol. 2017; 16(Suppl. 1: s3-105.): s4–ss14.
  11. Molinaro A, Wahlström A, Marschall HU. Role of Bile Acids in Metabolic Control. Trends Endocrinol Metab. 2018; 29(1): 31–41.
  12. Chiang JYL, Ferrell JM. Bile Acid Biology, Pathophysiology, and Therapeutics. Clin Liver Dis (Hoboken). 2020; 15(3): 91–94.
  13. Tayyar A, Temel Yuksel I, Koroglu N, et al. Maternal copeptin levels in intrahepatic cholestasis of pregnancy. J Matern Fetal Neonatal Med. 2018; 31(15): 2066–2070.
  14. Ballatori N, Christian WV, Lee JY, et al. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology. 2005; 42(6): 1270–1279.
  15. Boyer JL. OSTα-OSTβ Guards the Ileal Enterocyte From the Accumulation of Toxic Levels of Bile Acids. Cell Mol Gastroenterol Hepatol. 2018; 5(4): 649–650.
  16. Boyer JL, Trauner M, Mennone A, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol. 2006; 290(6): G1124–G1130.
  17. Schaap FG, van der Gaag NA, Gouma DJ, et al. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology. 2009; 49(4): 1228–1235.
  18. Malinen MM, Ali I, Bezençon J, et al. Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury. Am J Physiol Gastrointest Liver Physiol. 2018; 314(5): G597–G609.
  19. Chai J, Feng X, Zhang L, et al. Hepatic expression of detoxification enzymes is decreased in human obstructive cholestasis due to gallstone biliary obstruction. PLoS One. 2015; 10(3): e0120055.
  20. Soroka CJ, Mennone A, Hagey LR, et al. Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. Hepatology. 2010; 51(1): 181–190.
  21. Van De Wiel S. Intestinal transport and signaling of bile salts: A focus on OSTα-OSTβ. 2020.
  22. Vaz FM, Paulusma CC, Huidekoper H, et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology. 2015; 61(1): 260–267.
  23. Kojima H, Nies AT, König J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol. 2003; 39(5): 693–702.
  24. Van Herpe F, Waterham HR, Adams CJ, et al. NTCP deficiency and persistently raised bile salts: an adult case. J Inherit Metab Dis. 2017; 40(3): 313–315.
  25. Sargiacomo C, El-Kehdy H, Pourcher G, et al. Age-dependent glycosylation of the sodium taurocholate cotransporter polypeptide: From fetal to adult human livers. Hepatol Commun. 2018; 2(6): 693–702.
  26. Shneider BL, Fox VL, Schwarz KB, et al. Hepatic basolateral sodium-dependent-bile acid transporter expression in two unusual cases of hypercholanemia and in extrahepatic biliary atresia. Hepatology. 1997; 25(5): 1176–1183.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl